{"transactions":[{"id":4634177,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":51041,"kind":"person","name":"Raben David","position":1,"cik":"0002034679","reported_name":"Raben David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:20:33.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":575000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to such option vest and become exercisable on September 30, 2027, and the remaining seventy-five percent (75%) of the shares subject to the option vest and become exercisable in substantially equal installments thereafter on each monthly anniversary of September 30, 2027 (or if there is no corresponding day in any such month, on the last day of each month) over three (3) years, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":575000,"derivative":{"exercise_price":1.05,"expiration_date":"2036-10-01","underlying":"Common Stock","underlying_shares":575000},"source":{"system":"sec-edgar","filing":"0001746473-26-000117","document":"wk-form4_1790972430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034679/000174647326000117/wk-form4_1790972430.xml","form_type":"4"}},{"id":710619,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":18427,"kind":"person","name":"Iannone Robert","position":1,"cik":"0001737329","reported_name":"Iannone Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T20:32:28.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":60000,"derivative":{"exercise_price":1.13,"expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001737329-26-000013","document":"wk-form4_1783974746.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737329/000173732926000013/wk-form4_1783974746.xml","form_type":"4"}},{"id":710405,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":30726,"kind":"person","name":"Borellini Flavia","position":1,"cik":"0001867426","reported_name":"Borellini Flavia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T20:32:14.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":60000,"derivative":{"exercise_price":1.13,"expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001867426-26-000004","document":"wk-form4_1783974731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000186742626000004/wk-form4_1783974731.xml","form_type":"4"}},{"id":739797,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:01:14.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000102","document":"wk-form4_1781298070.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1666236/000174647326000102/wk-form4_1781298070.xml","form_type":"4"}},{"id":739436,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38632,"kind":"person","name":"CROWELL GAYLE A","position":1,"cik":"0001250893","reported_name":"CROWELL GAYLE A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:01:27.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000104","document":"wk-form4_1781298082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250893/000174647326000104/wk-form4_1781298082.xml","form_type":"4"}},{"id":739751,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38715,"kind":"person","name":"MCCOURT Thomas A","position":1,"cik":"0001478448","reported_name":"MCCOURT Thomas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:01:20.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000103","document":"wk-form4_1781298078.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478448/000174647326000103/wk-form4_1781298078.xml","form_type":"4"}},{"id":739232,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:01:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000101","document":"wk-form4_1781298064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000174647326000101/wk-form4_1781298064.xml","form_type":"4"}},{"id":739574,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:00:59.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000100","document":"wk-form4_1781298056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000174647326000100/wk-form4_1781298056.xml","form_type":"4"}},{"id":739152,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:00:51.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000099","document":"wk-form4_1781298048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633639/000174647326000099/wk-form4_1781298048.xml","form_type":"4"}},{"id":805100,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":55200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":55200,"derivative":{"exercise_price":1.33,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":55200},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805099,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":55200},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805098,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.33,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805097,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805096,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1.33,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805095,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.18,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805723,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":113300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":113300,"derivative":{"exercise_price":1.33,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":113300},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805722,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":113300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":113300},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805721,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":110500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":110500,"derivative":{"exercise_price":1.33,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":110500},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805720,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":110500},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805719,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":76200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033."}],"balance_after":76200,"derivative":{"exercise_price":1.33,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":76200},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805718,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033."}],"balance_after":0,"derivative":{"exercise_price":34.65,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":76200},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805717,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032."}],"balance_after":124000,"derivative":{"exercise_price":1.33,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805716,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032."}],"balance_after":0,"derivative":{"exercise_price":11.86,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805715,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":74250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031."}],"balance_after":74250,"derivative":{"exercise_price":1.33,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":74250},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805714,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031."}],"balance_after":0,"derivative":{"exercise_price":26.5,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":74250},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805713,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":18198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030."}],"balance_after":18198,"derivative":{"exercise_price":1.33,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":18198},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805712,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030."}],"balance_after":0,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":18198},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805711,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":76047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029."}],"balance_after":76047,"derivative":{"exercise_price":1.33,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":76047},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805710,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:44.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76047,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":76047},"source":{"system":"sec-edgar","filing":"0001746473-26-000054","document":"wk-form4_1776458561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000054/wk-form4_1776458561.xml","form_type":"4"}},{"id":805709,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":325000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805708,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":0,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805707,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":256300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":256300,"derivative":{"exercise_price":1.33,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":256300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805706,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":256300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":256300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805705,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":206300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033."}],"balance_after":206300,"derivative":{"exercise_price":1.33,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":206300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805704,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":206300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033."}],"balance_after":0,"derivative":{"exercise_price":34.65,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":206300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805703,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032."}],"balance_after":440000,"derivative":{"exercise_price":1.33,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805702,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032."}],"balance_after":0,"derivative":{"exercise_price":11.86,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805701,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031."}],"balance_after":250000,"derivative":{"exercise_price":1.33,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805700,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031."}],"balance_after":0,"derivative":{"exercise_price":26.5,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805699,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":327262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030."}],"balance_after":327262,"derivative":{"exercise_price":1.33,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":327262},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805698,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":327262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030."}],"balance_after":0,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":327262},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805697,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":146841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029."}],"balance_after":146841,"derivative":{"exercise_price":1.33,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":146841},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805696,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":146841},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805094,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:32.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":51750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":51750,"derivative":{"exercise_price":1.33,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":51750},"source":{"system":"sec-edgar","filing":"0001746473-26-000052","document":"wk-form4_1776458549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000052/wk-form4_1776458549.xml","form_type":"4"}},{"id":805093,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:32.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":51750},"source":{"system":"sec-edgar","filing":"0001746473-26-000052","document":"wk-form4_1776458549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000052/wk-form4_1776458549.xml","form_type":"4"}},{"id":805092,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:32.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":52000,"derivative":{"exercise_price":1.33,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001746473-26-000052","document":"wk-form4_1776458549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000052/wk-form4_1776458549.xml","form_type":"4"}},{"id":805091,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:32.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001746473-26-000052","document":"wk-form4_1776458549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000052/wk-form4_1776458549.xml","form_type":"4"}},{"id":805090,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:32.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":123000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 4 originally filed on January 23, 2023 from January 18, 2033 to the correct expiration date of January 19, 2033."}],"balance_after":123000,"derivative":{"exercise_price":1.33,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":123000},"source":{"system":"sec-edgar","filing":"0001746473-26-000052","document":"wk-form4_1776458549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000052/wk-form4_1776458549.xml","form_type":"4"}},{"id":805089,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:32.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":123000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 4 originally filed on January 23, 2023 from January 18, 2033 to the correct expiration date of January 19, 2033."}],"balance_after":0,"derivative":{"exercise_price":21.935,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":123000},"source":{"system":"sec-edgar","filing":"0001746473-26-000052","document":"wk-form4_1776458549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000052/wk-form4_1776458549.xml","form_type":"4"}},{"id":931208,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:36:53.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":400000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001746473-26-000020","document":"wk-form4_1769463411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000020/wk-form4_1769463411.xml","form_type":"4"}},{"id":930967,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:36:47.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":300000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001746473-26-000019","document":"wk-form4_1769463404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000019/wk-form4_1769463404.xml","form_type":"4"}},{"id":930965,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:36:41.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":300000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001746473-26-000018","document":"wk-form4_1769463399.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000018/wk-form4_1769463399.xml","form_type":"4"}},{"id":931207,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:36:35.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":1230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":1230000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":1230000},"source":{"system":"sec-edgar","filing":"0001746473-26-000017","document":"wk-form4_1769463393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000017/wk-form4_1769463393.xml","form_type":"4"}},{"id":933468,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-23T02:46:38.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":24002,"price":1.28,"value":30722.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,958 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":297214,"source":{"system":"sec-edgar","filing":"0001746473-26-000012","document":"wk-form4_1769136395.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647326000012/wk-form4_1769136395.xml","form_type":"4"}},{"id":933135,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Common Stock","published_at":"2026-01-23T02:38:38.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":7534,"price":1.28,"value":9643.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,956 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":44847,"source":{"system":"sec-edgar","filing":"0001746473-26-000010","document":"wk-form4_1769135916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000010/wk-form4_1769135916.xml","form_type":"4"}},{"id":933451,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-23T02:38:33.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":89375,"price":1.28,"value":114400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,959 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase program."}],"balance_after":505601,"source":{"system":"sec-edgar","filing":"0001746473-26-000009","document":"wk-form4_1769135911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000009/wk-form4_1769135911.xml","form_type":"4"}},{"id":933134,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-23T02:38:28.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":6917,"price":1.28,"value":8853.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":37806,"source":{"system":"sec-edgar","filing":"0001746473-26-000008","document":"wk-form4_1769135906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000008/wk-form4_1769135906.xml","form_type":"4"}},{"id":1117502,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-10T00:44:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000132","document":"wk-form4_1749516282.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000174647325000132/wk-form4_1749516282.xml","form_type":"4"}},{"id":1117319,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-10T00:44:41.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000131","document":"wk-form4_1749516267.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000131/wk-form4_1749516267.xml","form_type":"4"}},{"id":1117870,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-10T00:43:55.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000128","document":"wk-form4_1749516225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1666236/000174647325000128/wk-form4_1749516225.xml","form_type":"4"}},{"id":1118549,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34936,"kind":"person","name":"PYOTT DAVID E I","position":1,"cik":"0001051578","reported_name":"PYOTT DAVID E I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-10T00:43:25.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000126","document":"wk-form4_1749516194.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1051578/000174647325000126/wk-form4_1749516194.xml","form_type":"4"}},{"id":1117830,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38715,"kind":"person","name":"MCCOURT Thomas A","position":1,"cik":"0001478448","reported_name":"MCCOURT Thomas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:44:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000130","document":"wk-form4_1749516254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478448/000174647325000130/wk-form4_1749516254.xml","form_type":"4"}},{"id":1117434,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:44:11.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000129","document":"wk-form4_1749516237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000174647325000129/wk-form4_1749516237.xml","form_type":"4"}},{"id":1117356,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:43:44.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000127","document":"wk-form4_1749516208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633639/000174647325000127/wk-form4_1749516208.xml","form_type":"4"}},{"id":1117740,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:43:08.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000125","document":"wk-form4_1749516175.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000174647325000125/wk-form4_1749516175.xml","form_type":"4"}},{"id":1117561,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38632,"kind":"person","name":"CROWELL GAYLE A","position":1,"cik":"0001250893","reported_name":"CROWELL GAYLE A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:42:49.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000124","document":"wk-form4_1749516160.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250893/000174647325000124/wk-form4_1749516160.xml","form_type":"4"}},{"id":1294162,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T23:14:06.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":51750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":51750,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":51750},"source":{"system":"sec-edgar","filing":"0001746473-25-000019","document":"wk-form4_1738019640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000019/wk-form4_1738019640.xml","form_type":"4"}},{"id":1294161,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:14:06.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":25875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":50425,"source":{"system":"sec-edgar","filing":"0001746473-25-000019","document":"wk-form4_1738019640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000019/wk-form4_1738019640.xml","form_type":"4"}},{"id":1294160,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83855,"kind":"person","name":"Ouimette Mike","position":1,"cik":"0001822619","reported_name":"Ouimette Mike","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Corp. Sec'y"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T23:10:00.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":70000,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-25-000017","document":"wk-form4_1738019393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000017/wk-form4_1738019393.xml","form_type":"4"}},{"id":1294159,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83855,"kind":"person","name":"Ouimette Mike","position":1,"cik":"0001822619","reported_name":"Ouimette Mike","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Corp. Sec'y"}}],"security":"Common Stock","published_at":"2025-01-27T23:10:00.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":105544,"source":{"system":"sec-edgar","filing":"0001746473-25-000017","document":"wk-form4_1738019393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000017/wk-form4_1738019393.xml","form_type":"4"}},{"id":1294561,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T23:01:38.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":113300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":113300,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":113300},"source":{"system":"sec-edgar","filing":"0001746473-25-000011","document":"wk-form4_1738018892.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647325000011/wk-form4_1738018892.xml","form_type":"4"}},{"id":1294560,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:01:38.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":56650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":319258,"source":{"system":"sec-edgar","filing":"0001746473-25-000011","document":"wk-form4_1738018892.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647325000011/wk-form4_1738018892.xml","form_type":"4"}},{"id":1294559,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T22:58:27.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":325000,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001746473-25-000009","document":"wk-form4_1738018700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647325000009/wk-form4_1738018700.xml","form_type":"4"}},{"id":1294558,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-27T22:58:27.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":593017,"source":{"system":"sec-edgar","filing":"0001746473-25-000009","document":"wk-form4_1738018700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647325000009/wk-form4_1738018700.xml","form_type":"4"}},{"id":1294209,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T18:07:17.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":80300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":80300,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":80300},"source":{"system":"sec-edgar","filing":"0001746473-25-000015","document":"wk-form4_1738019230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647325000015/wk-form4_1738019230.xml","form_type":"4"}},{"id":1294208,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:07:17.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":40150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":251708,"source":{"system":"sec-edgar","filing":"0001746473-25-000015","document":"wk-form4_1738019230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647325000015/wk-form4_1738019230.xml","form_type":"4"}},{"id":1294421,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T18:04:15.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":91300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":91300,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":91300},"source":{"system":"sec-edgar","filing":"0001746473-25-000013","document":"wk-form4_1738019047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647325000013/wk-form4_1738019047.xml","form_type":"4"}},{"id":1294420,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:04:15.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":45650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":240224,"source":{"system":"sec-edgar","filing":"0001746473-25-000013","document":"wk-form4_1738019047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647325000013/wk-form4_1738019047.xml","form_type":"4"}},{"id":1297776,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-22T23:07:10.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":52419,"price":11.2011,"value":587150.4609,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":430517,"source":{"system":"sec-edgar","filing":"0001746473-25-000006","document":"wk-form4_1737587223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647325000006/wk-form4_1737587223.xml","form_type":"4"}},{"id":1297775,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-22T23:05:28.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":20148,"price":11.2011,"value":225679.7628,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 641 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":262608,"source":{"system":"sec-edgar","filing":"0001746473-25-000005","document":"wk-form4_1737587121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647325000005/wk-form4_1737587121.xml","form_type":"4"}},{"id":1297192,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52030,"kind":"person","name":"Cheung Lily","position":1,"cik":"0001962207","reported_name":"Cheung Lily","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resource Officer"}}],"security":"Common Stock","published_at":"2025-01-22T22:58:17.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":3740,"price":11.2011,"value":41892.114,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,495 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":24550,"source":{"system":"sec-edgar","filing":"0001746473-25-000002","document":"wk-form4_1737586689.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000002/wk-form4_1737586689.xml","form_type":"4"}},{"id":1297191,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83855,"kind":"person","name":"Ouimette Mike","position":1,"cik":"0001822619","reported_name":"Ouimette Mike","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Corp. Sec'y"}}],"security":"Common Stock","published_at":"2025-01-22T22:55:27.000Z","date":"2025-01-22","kind":"sale","planned":true,"acquired":false,"shares":10230,"price":10.9934,"value":112462.482,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 26, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $10.88 to $11.21, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":70544,"source":{"system":"sec-edgar","filing":"0001746473-25-000001","document":"wk-form4_1737586520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000001/wk-form4_1737586520.xml","form_type":"4"}},{"id":1297190,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83855,"kind":"person","name":"Ouimette Mike","position":1,"cik":"0001822619","reported_name":"Ouimette Mike","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Corp. Sec'y"}}],"security":"Common Stock","published_at":"2025-01-22T22:55:27.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":13270,"price":11.2011,"value":148638.597,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":80774,"source":{"system":"sec-edgar","filing":"0001746473-25-000001","document":"wk-form4_1737586520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000001/wk-form4_1737586520.xml","form_type":"4"}},{"id":1297218,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-22T18:02:33.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":15936,"price":11.2011,"value":178500.7296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":211558,"source":{"system":"sec-edgar","filing":"0001746473-25-000004","document":"wk-form4_1737586946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647325000004/wk-form4_1737586946.xml","form_type":"4"}},{"id":1297527,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-22T18:00:36.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":18478,"price":11.2011,"value":206973.9258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":194574,"source":{"system":"sec-edgar","filing":"0001746473-25-000003","document":"wk-form4_1737586829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647325000003/wk-form4_1737586829.xml","form_type":"4"}},{"id":1455364,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-07-12T22:37:28.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":10911,"price":11.56,"value":126131.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":282115,"source":{"system":"sec-edgar","filing":"0001746473-24-000125","document":"wk-form4_1720823841.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647324000125/wk-form4_1720823841.xml","form_type":"4"}},{"id":1455363,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-12T22:22:25.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":38710,"price":11.56,"value":447487.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":482936,"source":{"system":"sec-edgar","filing":"0001746473-24-000123","document":"wk-form4_1720822935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000123/wk-form4_1720822935.xml","form_type":"4"}},{"id":1455135,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83855,"kind":"person","name":"Ouimette Mike","position":1,"cik":"0001822619","reported_name":"Ouimette Mike","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Corp. Sec'y"}}],"security":"Common Stock","published_at":"2024-07-12T22:15:25.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":7656,"price":11.56,"value":88503.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":94044,"source":{"system":"sec-edgar","filing":"0001746473-24-000121","document":"wk-form4_1720822518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000121/wk-form4_1720822518.xml","form_type":"4"}},{"id":1455318,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-12T18:45:16.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":12319,"price":11.56,"value":142407.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":213052,"source":{"system":"sec-edgar","filing":"0001746473-24-000129","document":"wk-form4_1720824309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000129/wk-form4_1720824309.xml","form_type":"4"}},{"id":1455150,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-07-12T18:41:16.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":9900,"price":11.56,"value":114444.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":227494,"source":{"system":"sec-edgar","filing":"0001746473-24-000127","document":"wk-form4_1720824069.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000127/wk-form4_1720824069.xml","form_type":"4"}},{"id":1456309,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52059,"kind":"person","name":"Cummings Keith Lamont","position":1,"cik":"0001809204","reported_name":"Cummings Keith Lamont","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-07-11T20:54:13.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":21313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 21,313 shares."}],"balance_after":293026,"source":{"system":"sec-edgar","filing":"0001746473-24-000115","document":"wk-form4_1720731247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809204/000174647324000115/wk-form4_1720731247.xml","form_type":"4"}},{"id":1456308,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-11T20:47:45.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":75625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 75,625 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,489 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":521646,"source":{"system":"sec-edgar","filing":"0001746473-24-000113","document":"wk-form4_1720730857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000113/wk-form4_1720730857.xml","form_type":"4"}},{"id":1455788,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83855,"kind":"person","name":"Ouimette Mike","position":1,"cik":"0001822619","reported_name":"Ouimette Mike","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Corp. Sec'y"}}],"security":"Common Stock","published_at":"2024-07-11T20:41:53.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":14954,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 54,374 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 14,954 shares."}],"balance_after":101700,"source":{"system":"sec-edgar","filing":"0001746473-24-000111","document":"wk-form4_1720730506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000111/wk-form4_1720730506.xml","form_type":"4"}},{"id":1456155,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83859,"kind":"person","name":"Lefebvre Eric","position":1,"cik":"0001614741","reported_name":"Lefebvre Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-11T17:01:03.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":24063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various  pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":225371,"source":{"system":"sec-edgar","filing":"0001746473-24-000119","document":"wk-form4_1720731654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614741/000174647324000119/wk-form4_1720731654.xml","form_type":"4"}},{"id":1455845,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-07-11T16:58:42.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":19337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 70,312 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 19,337 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":237394,"source":{"system":"sec-edgar","filing":"0001746473-24-000117","document":"wk-form4_1720731516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000117/wk-form4_1720731516.xml","form_type":"4"}},{"id":1476811,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":39150,"kind":"person","name":"Knobil Katharine","position":1,"cik":"0001768011","reported_name":"Knobil Katharine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-18T00:16:29.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000107","document":"wk-form4_1718669781.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000107/wk-form4_1718669781.xml","form_type":"4"}},{"id":1477771,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34936,"kind":"person","name":"PYOTT DAVID E I","position":1,"cik":"0001051578","reported_name":"PYOTT DAVID E I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-18T00:16:03.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000105","document":"wk-form4_1718669756.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1051578/000174647324000105/wk-form4_1718669756.xml","form_type":"4"}},{"id":1476945,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-18T00:15:21.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000101","document":"wk-form4_1718669714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000174647324000101/wk-form4_1718669714.xml","form_type":"4"}},{"id":1477305,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":32853,"kind":"person","name":"Krognes Steve E.","position":1,"cik":"0001666236","reported_name":"Krognes Steve E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-17T23:57:19.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":53528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of June 13, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":53528,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":53528},"source":{"system":"sec-edgar","filing":"0001746473-24-000090","document":"wk-form4_1718668632.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1666236/000174647324000090/wk-form4_1718668632.xml","form_type":"4"}},{"id":1477261,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38715,"kind":"person","name":"MCCOURT Thomas A","position":1,"cik":"0001478448","reported_name":"MCCOURT Thomas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-17T20:16:39.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000108","document":"wk-form4_1718669792.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478448/000174647324000108/wk-form4_1718669792.xml","form_type":"4"}}],"next_cursor":"2024-06-17T20:16:39.000000Z,1477261"}